Methemoglobinemia natural history, complications and prognosis: Difference between revisions
| Line 20: | Line 20: | ||
==Prognosis== | ==Prognosis== | ||
*Depending on the [[anoxic end-organ damage]] caused by [[MetHb]], the prognosiss varies between mild and fatal. <ref>{{ | *Depending on the [[anoxic end-organ damage]] caused by [[MetHb]], the prognosiss varies between mild and fatal. <ref name="pmid19082413">{{cite journal| author=do Nascimento TS, Pereira RO, de Mello HL, Costa J| title=Methemoglobinemia: from diagnosis to treatment. | journal=Rev Bras Anestesiol | year= 2008 | volume= 58 | issue= 6 | pages= 651-64 | pmid=19082413 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19082413 }} </ref> | ||
==References== | ==References== | ||
Revision as of 13:07, 15 June 2018
|
Methemoglobinemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Methemoglobinemia natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Methemoglobinemia natural history, complications and prognosis |
|
FDA on Methemoglobinemia natural history, complications and prognosis |
|
on Methemoglobinemia natural history, complications and prognosis |
|
Methemoglobinemia natural history, complications and prognosis in the news |
|
Blogs on Methemoglobinemia natural history, complications and prognosis |
|
Risk calculators and risk factors for Methemoglobinemia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Template:Aksiniya K. Stevasarova, M.D.
Overview
Depending on the causes that have led to methemoglobin formation, we expect different complications and prognosis.
Natural History
- Patients with hereditary forms of methemoglobinemia are generally asymptomatic, with the exception of having chronic cyanosis. Unfortunately, despite the benign nature of the congenital methemoglobinemia, people with type IIb5 cytochrome-reductase deficiency have poor prognosis and shorter lifespan, mainly due to neurologic complications.
- In acquired methemoglobinemia, depending on the amount and duration of toxin exposure, the levels of MetHb in the blood will be different. As a result we expect different outcomes, which are as follows: MetHb of 15% presents with skin and blood color changes at levels; levels above 15% will result in hypoxia and levels above 70% can lead to death. [1] [2]
Complications
- Death is the most serious complications of methemoglobinemia especially when MetHb levels approach 70%. In severely sick patients death may occur even with lower levels of MetHb.
- Other complications include myocardial infarction, seizure and coma. [2]
Prognosis
- Depending on the anoxic end-organ damage caused by MetHb, the prognosiss varies between mild and fatal. [1]
References
- ↑ 1.0 1.1 do Nascimento TS, Pereira RO, de Mello HL, Costa J (2008). "Methemoglobinemia: from diagnosis to treatment". Rev Bras Anestesiol. 58 (6): 651–64. PMID 19082413.
- ↑ 2.0 2.1 Bradberry SM (2003). "Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue". Toxicol Rev. 22 (1): 13–27. PMID 14579544.